Cancer Embryonic Antigen: A New Breakthrough in Cancer Diagnosis
Cancer is one of the most prevalent diseases in the world. It affects millions of people every year and is responsible for countless deaths. Despite the advancements in medical technology, cancer remains a challenging disease to treat. One of the reasons for this is the difficulty in diagnosing cancer early. Now, there is a new hope in cancer diagnosis–the Cancer Embryonic Antigen (CEA).
CEA is a protein that is produced during fetal development. It is present in small amounts in healthy adults, but its level increases significantly in people with certain types of cancer, such as colorectal, lung, and breast cancer. Therefore, CEA can be used as a biomarker for cancer diagnosis.
In recent years, there have been significant advancements in CEA testing. The Carcinoembryonic antigen testing independently developed and produced by Xiamen Wiz Biotech Co., Ltd., uses the high specificity double antibody sandwich reaction principle and fluorescence immunochromatographic analysis technology. The test can detect CEA at very low levels, making it more accurate in cancer diagnosis. In addition, the test is non-invasive and can be done using a simple blood sample.
The Carcinoembryonic antigen assay kit produced by Wizbiotech now is available in laboratories and clinics around the world. As more and more healthcare professionals realize its benefits, its adoption is expected to continue to grow.
Wizbiotech always takes "focus on diagnostic technology, improve the quality of life" as its purpose, focuses on technological innovation, and hopes to contribute more in the field of POCT rapid diagnosis.
For further information, please contact WIZ’s sales team.
